Hindler Janet F, Stelling John
University of California Los Angeles Medical Center, Los Angeles, CA 90095-1713, USA.
Clin Infect Dis. 2007 Mar 15;44(6):867-73. doi: 10.1086/511864. Epub 2007 Feb 8.
It is crucial to monitor emerging trends in resistance at the local level to support clinical decision making, infection-control interventions, and antimicrobial-resistance containment strategies. Monitoring of antimicrobial resistance trends is commonly performed in health care facilities using an annual summary of susceptibility rates, known as a cumulative antibiogram report. The Clinical and Laboratory Standards Institute M39-A2 consensus document, entitled "Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data," provides guidance to clinical laboratories in the preparation of a cumulative antibiogram. The purpose of this review is to describe this document, explain the rationale for some of the recommendations, discuss limitations of its use, and propose new directions for future revisions. The document contains specific recommendations for the collection, storage, analysis, and presentation of data and includes sample templates highlighting the recommendations. Critical issues include the recommended frequency of reporting, the number of isolates to include in a statistic, and a mechanism for eliminating multiple isolates of a given bacterial species obtained from an individual patient.
在地方层面监测耐药性的新趋势对于支持临床决策、感染控制干预措施以及抗菌药物耐药性遏制策略至关重要。在医疗机构中,通常使用药敏率年度总结(即累积抗菌谱报告)来监测抗菌药物耐药性趋势。临床和实验室标准协会的M39 - A2共识文件,题为《累积抗菌药物敏感性试验数据的分析与呈现》,为临床实验室编制累积抗菌谱提供了指导。本综述的目的是描述该文件,解释部分建议的依据,讨论其使用的局限性,并为未来修订提出新方向。该文件包含了数据收集、存储、分析和呈现的具体建议,并包括突出这些建议的示例模板。关键问题包括推荐的报告频率、纳入统计的分离株数量,以及消除从单个患者获得的给定细菌物种的多个分离株的机制。